Taxing opioids once looked like the next big revenue opportunity for states. But while taxes on sports betting, marijuana, and vaping products have become common, only New York has followed through with an opioid tax, which partially backfired.

Two of the big forces behind the trend: First, most states are embracing a big, one-time payout through legal settlements with opioid manufacturers and distributors. Second, state tax and health care professionals have criticized levying what appears to be a “sin tax” on a medicine that fulfills a critical need for those who suffer from chronic pain.

“A tax on opioids isn’t like a standard sin tax,” Nicole Kaeding, vice president of Policy Promotion at the National Taxpayers Union Foundation said. “Excise taxes on substances like alcohol and cigarettes are meant to dissuade use, but many people need opioids, and obviously not everybody taking them is abusing them.”

And ultimately, the tax would be paid by patients, not by the drug companies, said Richard Auxier, a research associate at the Urban-Brookings Tax Policy Center.

“There’s this effort to try and get ‘Big Pharma companies’ to pay an additional excise tax on the production of opioids, but if pursued the tax would surely be pushed on the consumer, and that would be problematic,” Auxier said. “This isn’t like going to 7/11 to get a pack of cigarettes; this is medicine.”

Legal settlements totaling into the billions have surfaced in past weeks—$260 million in Ohio, $572 in Oklahoma, and a $3 billion Purdue Pharma, Inc. settlement spanning across 23 states among them.

Follow the Lawsuits

Kaeding compared the wave of lawsuits to the Tobacco Master Settlement Agreement (MSA) of the late 1990s. In the MSA, attorneys general of 46 states won more than $200 billion in damages from the four largest tobacco companies, to be paid over the first 25 years of the agreement.

Auxier of the Tax Policy Center said he doesn’t expect more states to go after a similar law in the upcoming year. “If states were hesitant to do this in 2018, then they’ll still be hesitant in 2020,” he said.

Other states have considered an opioid tax as recent as this year—including Massachusetts, Maine, and Minnesota—but none have followed through.

Lawmakers from these state have not responded for a request for comment on specific factors contributing to the downfall of the proposed taxes.

The Problem in New York


Bloomberg Tax & Accounting

New York on July 1 became the first state to enact an excise tax targeting opioids. The New York experiment, however, has triggered some unexpected consequences.

“It is very unusual to tax medicine in this manner; a lot of people using opioids are using them legitimately” said Bill Hammond, director of health policy at The Empire Center, a conservative-leaning think tank in Albany, N.Y. “To go after a specific class of drug like this, I don’t think anything like this has ever been done in New York.”

“I think that in advancing this bill, the state saw Big Pharma as a ‘boogie man’ that they could try and tax without repercussions, but it clearly hasn’t played out that way,” Hammond said.

According to Hammond, New York has set a targeted goal of $100 million in opioid excise tax revenue per year.

Freeman Klopott, spokesperson for the New York State Division of the Budget, argued that the money generated from the excise tax would benefit patients.

“New York State is spending over $1 billion to deal with the aftermath of the opioid industry’s unscrupulous distribution of drugs across the country and the death and misery that has resulted in every community,” Klopott said in an email. “The State will work to ensure patients continue to have access to the medicine they need while this new tax is projected to generate $100 million to help offset these incredible costs.”

However, the new tax has triggered a business backlash. Some opioid manufacturers have already pulled out of the state, affecting those with opioid prescriptions and hurting revenue.

According to Kaeding, three manufacturers—Epic Pharma, AvKARE and Lupin Pharmaceuticals—discontinued opioid shipments to the Empire State soon after the law was effective. Two other manufacturers, Mallinckrodt Pharmaceuticals and Upsher-Smith Laboratories, are in talks over cutting ties with the state.

The law taxes opioid doses by the milligram, either by a quarter cent per milligram when the wholesale cost is less than 50 cents per dose, or one-and-a-half cents when the wholesale cost is 50 cents or more per dose. According to the statute, information about revenue generated by the law is to be kept secret.

The state had passed a similar law in 2018, but that was deemed unconstitutional by a federal judge who said that it violated the Commerce Clause in the U.S. Constitution.

© 2019 Bloomberg Law

You may also like

NY Health Department Asserts Cuomo Order ‘Could Not Be the Driver’ of Nursing-Home Deaths in the State

Zachary Evans The New York State Department of Health has concluded that an executive order requiring nursing homes to readmit coronavirus patients, issued by Governor Andrew Cuomo, was not the driving factor behind coronavirus deaths in the s Read More

EDITORIAL: Nursing home report requires a second opinion

It’s great that the Cuomo administration and its Health Department issued a report this week detailing the causes of nursing home deaths at the height of the state’s coronavirus outbreak. And it’s great that the department Read More

What we know (and don’t know) about NY COVID-19 nursing home deaths after DOH report

David Robinson The state Department of Health's own analysis of COVID-19 nursing home deaths has renewed politically the charged debate over how and why coronavirus ravaged the most vulnerable New Yorkers. Read More

Faced with $10B deficit, MTA says it’s eyeing cutting overtime spending

Alfonso Castillo The financial impact of the COVID-19 pandemic on the Metropolitan Transportation Authority is adding urgency to the agency’s efforts to curtail overtime numbers that critics say remain alarmingly high. The MTA said at Wed Read More

City and state officials contend with a dire future as New York reopens

Brian Pascus As New York begins to reopen from the Covid-19 lockdown, Read More

Pandemic, recession don’t bring down school budgets

Stephen T. Watson This year's school elections were delayed and then shifted entirely to voting by mail thanks to the Covid-19 pandemic, which also shut down schools here and across the country. District officials worried this new method of Read More

Here’s Cuomo’s Plan for Reopening New York

Jesse McKinley ALBANY, N.Y. — Gov. Andrew M. Cuomo on Monday presented a soft blueprint for how New York State’s economy might begi Read More

States with few virus cases get big share of relief aid

Geoff Mulvihill Alaska, Hawaii, Montana and Wyoming are not epicenters of the coronavirus pandemic. Yet these four states scored big this spri Read More


Sign up to receive updates about Empire Center research, news and events in your email.


Empire Center for Public Policy
30 South Pearl St.
Suite 1210
Albany, NY 12207

Phone: 518-434-3100
Fax: 518-434-3130


The Empire Center is an independent, non-partisan, non-profit think tank located in Albany, New York. Our mission is to make New York a better place to live and work by promoting public policy reforms grounded in free-market principles, personal responsibility, and the ideals of effective and accountable government.